Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

The approval of EYLEA was granted under a Priority Review, a designation that is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.  This approval was based upon the results of two Phase 3 clinical studies.  In these studies, EYLEA dosed every eight weeks, following three initial monthly injections, was clinically equivalent to the standard of care, Lucentis® (ranibizumab injection) dosed every four weeks, as measured by the primary endpoint of maintenance of visual acuity (less than 15 letters of vision loss on an eye chart) over 52 weeks.  The most common adverse reactions (frequency of 5% or more) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.  The adverse event profile was similar to that seen with ranibizumab.

"The approval of EYLEA offers a much needed new treatment option for patients with wet AMD," said Jeffrey Heier, M.D., a clinical ophthalmologist and retinal specialist at Ophthalmic Consultants of Boston, Assistant Professor of Ophthalmology at Tufts School of Medicine, and Chair of the Steering Committee for the VIEW 1 trial.
"EYLEA offers the potential of achieving the efficacy we've come to expect from current anti-VEGF agents, but with less frequent injections and no monitoring requirements.  This may reduce the need for cos
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... 21, 2013  Armada Health Care (Armada) is ... Armada corporate website ( www.armadahealthcare.com ).  This new ... and first-to-market services and its position as the ... specialty pharmacy industry. The updated website ... business model in delivering an extensive portfolio of ...
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
... 2011 Healthpoint today announced the launch of a ... Biotherapeutics, along with an updated brandmark and corporate tagline, ... is designed to communicate the company,s commitment to scientific ... contribute to improved outcomes and quality of life for ...
... Md., Feb. 23, 2011 The Cystic Fibrosis Foundation and ... development that targets the defective protein that causes cystic fibrosis, ... The trial was designed to evaluate patients age ... a CF mutation called G551D. The study included 161 patients ...
Cached Medicine Technology:Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
(Date:5/21/2013)... May 21, 2013 Medical Ministry International ... prestigious 2013 Top-Rated Award by GreatNonprofits , the leading ... excited to be named a Top-Rated 2013 Nonprofit,” says Samuel ... dedication of our over 3000 Volunteers and Staff serving in ... as it came from those that have seen our work ...
(Date:5/21/2013)... New York, New York (PRWEB) May 21, 2013 ... protecting the rights of victims injured by defective medical devices, ... attorney in the case of the Estate of Fred E. ... Kitsap County (Port Orchard). A May 21, 2013, Bloomberg ... Intuitive Surgical had acted like a “car dealership” in how ...
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 ContinuCare ... the Texas Department of Aging and Disability Services. After ... and employee interviews, ContinuCare Home Health was found ... The review is part of the Department of Aging ... of aging and disability services, supports and opportunities ...
(Date:5/21/2013)... HealthSmart continues to grow through strategic ... required the hiring of new talent in several areas, ... announce that Dawn Powell has joined the organization effective ... of Account Management in the Central Region and is ... With extensive client management, employee benefits, and product development ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
Breaking Medicine News(10 mins):Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2
... University School of Medicine in St. Louis, Missouri, have ... lead to treatments for deadliest poisons like Ricin, cholera ... the deadly strains of E. coli bacteria, these toxins ... the Golgi network and endoplasmic reticulum before interrupting protein ...
... from Eli Lilly and Company and the ... the genetic mutation that may alter tumour cell proliferation, ... ,The researchers say that they found a ... and ovarian cancers. ,The AKT pathway ...
... vineyards and launching an overseas marketing blitz under ... glut and countering New World producers. ,Farm ... wine budget of 1.3 billion euros (1.8 billion dollars) ... huge challenges facing the sector. ,"We are ...
... ended the six-year reign of a Japanese champion Wednesday, gobbling ... the annual Nathan's Famous Hot Dog Eating contest. ... streak to the cheers of a crowd of 50,000, according ... dropping out of the event after arthritis of the jaw ...
... protein that, in rats, rescues brain cells whose death ... the central nervous system. ,The new molecule, ... of cells that produce the key brain chemical dopamine ... ,Tested on lab rodents engineered to have Parkinson's, ...
... at the scene of a variety of tumors is implicated ... in a paper by researchers at The University of ... the Proceedings of the National Academy of Sciences. ... that its actually causing cancer. In this paper we show ...
Cached Medicine News:Health News:Genetic Mutation That Makes Common Cancers Resistant to Drugs Identified 2Health News:EU Aims to Shake Up Wine Industry With Root-and-branch Reform 2Health News:American Bests Japanese Hot Dog Eating Champion, Sets Record 2Health News:New Oncogene for Brain Cancer 2Health News:New Oncogene for Brain Cancer 3
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • Not available with casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: